Smart Nanoarchitectures for Precision RNA Delivery: Harnessing Endogenous and Exogenous Stimuli in Cancer Treatment

Jianying Hao, Yue Li, Xuhui Huang, Nannan Qi, Yanan Sun, Chaoxing He, Shaokun Yang, Zhi-Yun Niu, Xian Qi, Bai XiangTheranostics 2025 · DOI

This review article, published in Theranostics (2025), provides a comprehensive overview of the "smart" nanocarriers designed to overcome the formidable physiological barriers to RNA delivery in cancer treatment. By leveraging the unique biochemical signatures of the tumor microenvironment (TME) or external physical triggers, these nanoarchitectures enable the precise, spatiotemporal release of therapeutic RNA.

TL;DR

This paper reviews the transition from passive to "intelligent" RNA delivery systems that respond to specific stimuli—like tumor acidity, high redox potential, or external light—to ensure RNA reaches its intracellular target. It highlights how these smart nanoarchitectures are overcoming the "delivery bottleneck" to move RNA therapies from the lab into clinical reality.

What Problem Does This Paper Address?

RNA therapies (mRNA, siRNA, CRISPR/Cas9) offer a "simplified molecular design" to treat cancer by regulating gene expression. However, RNA is inherently unstable. When injected into the body, it faces a gauntlet of barriers:

  1. Rapid Degradation: Circulating nucleases chew up free RNA almost instantly.
  2. Immune Clearance: The mononuclear phagocyte system (MPS) recognizes and removes foreign particles.
  3. The "PEG Dilemma": Polyethylene glycol (PEG) coatings protect nanoparticles from the immune system but also hinder their ability to enter target cells.
  4. Endosomal Escape: Even if a nanoparticle enters a cell, it often gets trapped in acidic endosomes/lysosomes and degraded before it can reach the cytoplasm.

Traditional nanoparticles often lack the specificity to release their cargo only at the tumor site, leading to off-target toxicity and low therapeutic efficiency.

Methods

The authors categorize and analyze "smart" delivery strategies based on the type of trigger they use:

  • Endogenous Stimuli (Internal):
    • pH-Responsive: Utilizing the acidic nature of the TME (pH 6.5–6.8) and endosomes (pH 4.5–6.5) to trigger the cleavage of acid-labile bonds (like hydrazones or acetals) or the protonation of ionizable lipids to promote "endosomal escape" via the proton sponge effect.
  • Redox-Responsive: Exploiting the massive gradient of Glutathione (GSH)—which is 100–1000 times higher inside cancer cells than in the blood—to break disulfide or diselenide linkers.
  • Enzyme-Responsive: Designing carriers that disassemble when they encounter overexpressed tumor enzymes like Matrix Metalloproteinases (MMPs) or Cathepsin B.
  • Exogenous Stimuli (External):
    • Light/Ultrasound/Magnetic: Using Near-Infrared (NIR) light for deep tissue penetration, ultrasound-mediated cavitation to temporarily open the blood-brain barrier, or magnetic fields to physically guide nanoparticles to a lesion.
  • Advanced Design Tools: The paper highlights the emerging use of Machine Learning (ML) and Artificial Intelligence (AI) to screen vast libraries of ionizable lipids and predict which structures will be most effective for specific organs.

Datasets

As a review paper, it synthesizes data from hundreds of primary research articles and clinical trials. Notable "data-driven" approaches mentioned include:

  • High-Throughput Synthesis (HTS) Libraries: Studies using the Ugi four-component reaction to create libraries of 584+ ionizable lipids.
  • ML Frameworks: Systems like LiON (using neural networks) and XGBoost trained on thousands of data points (e.g., 9,302 LNP activity measurements) to predict pulmonary and muscle-specific gene delivery.
  • Clinical Trial Data: A summary of ongoing trials (Table 4), including high-profile candidates like Moderna’s mRNA-4157 (Phase III).

Key Insights and Ideas

  • The Shift to "Active Adaptation": The field is moving away from "passive" nanoparticles toward systems that actively adapt their surface chemistry (e.g., shedding a PEG layer) only upon reaching the tumor.
  • Multi-Stage/Cascade Response: The most effective systems are now "dual-responsive" (e.g., pH + Redox). For example, a nanoparticle might shed its protective shell in the acidic TME and then release its RNA cargo only once it senses the high GSH levels inside the cell.
  • The "Proton Sponge" Mechanism: A critical insight for grad students is the use of ionizable groups that "soak up" protons in the endosome, leading to an influx of chloride ions and water, which causes the endosome to swell and burst, releasing the RNA.
  • AI-Driven Discovery: The paper argues that the complexity of these "smart" systems has outpaced traditional trial-and-error chemistry, making AI-assisted design essential for the next generation of lipids.

Key Results

  • Enhanced Efficacy: Stimuli-responsive systems have demonstrated Tumor Inhibition Rates (TIR) of >80-90% in various animal models, significantly outperforming traditional "static" nanoparticles.
  • Improved Delivery: Light-activated "LASER" strategies have been shown to double the endosomal escape efficiency (from 1.0% to 2.1% or higher).
  • Clinical Translation: Several RNA-based immunotherapies are currently in Phase II and III trials, showing significant reductions in cancer recurrence (e.g., 49% reduction in recurrence for mRNA-4157 when combined with pembrolizumab).

Limitations and Future Work

  • Tumor Heterogeneity: Stimuli like pH and enzyme levels vary wildly between patients and even within different parts of the same tumor, making "universal" smart carriers difficult to design.
  • Manufacturing Complexity: The more "intelligent" a nanocarrier is, the harder it is to manufacture consistently at a large scale (the "batch-to-batch variability" problem).
  • Safety of Triggers: High-intensity ultrasound or UV light can cause tissue damage; future work must focus on safer, lower-energy triggers like NIR-II light.
  • Future Direction: The authors suggest that integrating single-cell omics and real-time TME monitoring will be necessary to truly personalize RNA delivery.

Summary updated

Abstract

RNA therapy holds great potential for cancer treatment owing to its ability to regulate gene expression precisely, thereby inhibiting tumor growth and metastasis. However, RNA delivery faces several physiological challenges, including rapid degradation by nucleases, limited cellular uptake, and inefficient intracellular release. To address these limitations, stimuli-responsive nanocarriers have been developed to enhance RNA delivery and improve therapeutic efficacy while minimizing side effects. These intelligent systems are designed to respond to specific endogenous or exogenous stimuli (<i>e.g.</i>, pH, redox potential, enzyme, light, magnetic fields, and ultrasound), enabling targeted delivery and controlled RNA release. This review highlights recent advances in the design and mechanisms of stimuli-responsive RNA nanocarriers, emphasizing key research findings and exploring future perspectives for their clinical translation.
BibTeX
@inproceedings{hao2025smart,
  author = {Jianying Hao and Yue Li and Xuhui Huang and Nannan Qi and Yanan Sun and Chaoxing He and Shaokun Yang and Zhi-Yun Niu and Xian Qi and Bai Xiang},
  title = {{Smart Nanoarchitectures for Precision RNA Delivery: Harnessing Endogenous and Exogenous Stimuli in Cancer Treatment}},
  booktitle = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.112492},
}
Figure